New embolization vs standard for liver cancer
Part of Cancer clinical trials.
This trial tests a new embolization treatment (TATE) against standard therapy for people with intermediate-stage liver cancer that hasn't spread. The goal is to see if TATE works better at controlling the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hepatocellular carcinoma (liver cancer) that has not spread outside the liver.
- You are in fairly good health (able to do daily activities with little help) and your liver and kidney function are working well enough.
- You have not had a liver transplant, radiation therapy, or prior embolization for liver tumors.
- Your overall health score (ECOG) is 0 or 1, meaning you can walk and take care of yourself.
- Your oxygen level at rest is 92% or above without needing extra oxygen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial studies different ways to place treatments inside the liver to control liver tumors when they can’t be removed with surgery or ablation. It may help certain people by improving how well the tumor is treated while keeping liver function safer.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.